MSX-4

MSX-4
Clinical data

Drug class	Adenosine A_2A receptor antagonist
Identifiers
IUPAC name L-valine-3-{8-[(E)-2-[3-methoxyphenyl)ethenyl]-7-methyl-1-propargylxanthine-3-yl}propyl ester
CAS Number	1072907-79-9
Chemical and physical data
Formula	C₂₆H₃₀N₅O₅
Molar mass	492.556 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES COC1=CC=CC(/C=C/C2N(C)C3=C(N(CCCOC(=O)[C@](C(C)C)N([H])[H])C(=O)N(CC#C)C3=O)N=2)=C1
InChI InChI=1S/C26H30N5O5/c1-6-13-31-24(32)22-23(30(26(31)34)14-8-15-36-25(33)21(27)17(2)3)28-20(29(22)4)12-11-18-9-7-10-19(16-18)35-5/h1,7,9-12,16-17H,8,13-15,27H2,2-5H3/b12-11+ Key:APBGNHUAEAMEBF-VAWYXSNFSA-N

MSX-4 is a selective adenosine A_2A receptor antagonist used in scientific research. It is a water-soluble amino acid ester prodrug of MSX-2, the active metabolite of the drug. MSX-4 reverses the motivational deficits induced by the dopamine D₂ receptor antagonist eticlopride in animals and hence has the capacity to produce pro-motivational effects. MSX-4 was first described in the scientific literature by 2008.